Brokerages Set GRAIL, Inc. (NASDAQ:GRAL) Price Target at $72.83
by Scott Moore · The Cerbat GemGRAIL, Inc. (NASDAQ:GRAL – Get Free Report) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $68.6250.
GRAL has been the subject of a number of recent analyst reports. Mizuho initiated coverage on GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective for the company. Canaccord Genuity Group reduced their price objective on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Wall Street Zen downgraded GRAIL from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Robert W. Baird set a $82.00 price objective on GRAIL in a research note on Friday, February 20th.
Get Our Latest Stock Report on GRAIL
GRAIL Trading Down 0.6%
Shares of GRAIL stock opened at $49.47 on Friday. The company has a market capitalization of $2.03 billion, a P/E ratio of -4.42 and a beta of 4.62. The stock has a fifty day simple moving average of $59.82 and a 200 day simple moving average of $79.58. GRAIL has a 12-month low of $25.56 and a 12-month high of $118.84.
GRAIL (NASDAQ:GRAL – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The firm had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%. On average, analysts predict that GRAIL will post -15.15 EPS for the current year.
Insider Buying and Selling at GRAIL
In other news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares of the company’s stock, valued at $13,012,596.48. This represents a 14.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua J. Ofman sold 61,665 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $3,078,316.80. Following the transaction, the president directly owned 371,216 shares in the company, valued at $18,531,102.72. This represents a 14.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 310,267 shares of company stock worth $15,485,396 in the last quarter. 1.85% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. N.E.W. Advisory Services LLC purchased a new position in shares of GRAIL during the 4th quarter valued at $26,000. Comerica Bank lifted its position in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of GRAIL during the 4th quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in GRAIL during the 4th quarter worth about $31,000. Finally, Intesa Sanpaolo S.p.A. purchased a new stake in GRAIL during the 4th quarter worth about $44,000.
GRAIL Company Profile
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.